Organigram Processing
About Organigram Processing
Organigram's processing division manufactures cannabis derivatives including vapes, edibles, and concentrates, leveraging BAT's strategic investment for next-generation product innovation.
Key Facts
- 1British American Tobacco invested CAD $221 million for a 19.9% stake and a product development partnership
- 2Achieved leading market share in Canadian edibles and vape categories with brands like SHRED
Latest News
Major Cannabis Stocks Plunge on Rescheduling Reality Check
TLRY, CGC, ACB, CRON, and OGI tumble as investors reassess limited impact of federal cannabis reclassification on Canadian operators and market fundamentals.
Cannabis Stocks Plunge as Rescheduling Optimism Fades
Major cannabis operators including TLRY, CGC, and ACB tumble as investors reassess limited impact from federal reclassification prospects.
Organigram Stock Faces U.S. Market Scrutiny Amid Cannabis Expansion
OGI's cannabis-focused strategy draws mixed reactions from U.S. investors as regulatory uncertainty clouds growth prospects in key markets.
OGI Stock: Can Organigram's Cannabis Strategy Win U.S. Investors?
Organigram Holdings faces scrutiny as investors question whether its cannabis-focused approach can deliver returns in an increasingly competitive North American market.
Frequently Asked Questions
What is Organigram's relationship with BAT?
British American Tobacco invested in Organigram and established a Centre of Excellence collaboration to develop next-generation cannabis delivery and extraction technologies.
What Cannabis 2.0 products does Organigram make?
Organigram produces vapes, gummies, chocolates, concentrates, and infused pre-rolls under brands including SHRED, Edison, and Monjour.
Products
- Cannabis Vape Products
- Edibles and Gummies
- Cannabis Concentrates
Specialties
Company Details
- Type
- Extraction
- Location
- Moncton, NB, Canada
- Founded
- 2013
- Publicly Traded
- Yes
- Ticker
- NASDAQ:OGI